2020
DOI: 10.1016/j.msard.2020.102020
|View full text |Cite
|
Sign up to set email alerts
|

End of dose interval symptoms in patients treated with natalizumab: A role for serum cytokines?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
12
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 8 publications
(13 citation statements)
references
References 21 publications
1
12
0
Order By: Relevance
“…The most frequently reported symptom was fatigue, comparable to the natalizumab wearing-off phenomenon. [4][5][6][7] Most participants received EID of ocrelizumab based on CD19 B-cell counts to limit ocrelizumab exposure during the COVID-19 pandemic Treatment satisfaction was similar between the groups. Participants with a current wearing-off phenomenon significantly improved in self-reported physical and psychological functioning after ocrelizumab infusion.…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations
“…The most frequently reported symptom was fatigue, comparable to the natalizumab wearing-off phenomenon. [4][5][6][7] Most participants received EID of ocrelizumab based on CD19 B-cell counts to limit ocrelizumab exposure during the COVID-19 pandemic Treatment satisfaction was similar between the groups. Participants with a current wearing-off phenomenon significantly improved in self-reported physical and psychological functioning after ocrelizumab infusion.…”
Section: Discussionmentioning
confidence: 99%
“…3 Patients with MS using monoclonal antibodies can experience wearing-off at the end of a treatment cycle prior to the next dose. [4][5][6][7] The wearing-off phenomenon usually consists of an increase of MS-related symptoms such as fatigue, cognitive disability, balance problems, motor function problems or sensory symptoms, which disappear immediately or in the next days after infusion. The wearing-off phenomenon is reported by 50-70% of patients with MS using natalizumab, another monoclonal antibody registered for MS. [4][5][6][7] Regarding the natalizumab wearing-off phenomenon, an association with low natalizumab receptor occupancy was found.…”
Section: Introductionmentioning
confidence: 99%
See 2 more Smart Citations
“…Some retrospective studies are beginning to show that ExID schedules (ranging from 6 to 8 weeks) do not reduce efficacy of NTZ, although randomized trials are needed to evaluate safety, efficacy and PML risk reduction [5][6][7]. Many patients treated with NTZ experience wearing-off symptoms (WoS) towards the end of the administration cycle [8,9]. During the Sars-CoV-2 Giuseppe Magro and Stefania Barone Barone equally contributed to the manuscript.…”
Section: Introductionmentioning
confidence: 99%